James M. Hussey has been appointed president of Sagent Pharmaceuticals. Mr. Hussey will be responsible for commercial operations, including development, regulatory and supply chain activities, as well as having primary responsibility for the company’s sales, marketing and human Resources functions.
 
Mr. Hussey has more than 25 years of experience in the pharmaceutical and healthcare industries. Most recently he served as chief executive officer of NanoInk, a privately held nanolithography company, and vice president of strategic planning at Ovation Pharmaceuticals, a privately held pharmaceutical company. Prior to this, he worked for NeoPharm, Physician Quality Care, and Bristol-Myers Squibb.
 
"We are delighted to have Jim join the organization as our president," said Jeffrey M. Yordon, chief executive officer and chairman of the board of Sagent. "Given the growth trajectory we have experienced and our projected performance going forward, we want to provide seasoned leadership to our commercial operations while I continue to drive strategic development, develop partner relationships and investigate vertical integration. Jim has significant industry experience and knowledge of specialty pharmaceuticals and is a great addition to our leadership team. We look forward to his contributions as we move forward."